[go: up one dir, main page]

MX2017004043A - Derivados de acido boronico. - Google Patents

Derivados de acido boronico.

Info

Publication number
MX2017004043A
MX2017004043A MX2017004043A MX2017004043A MX2017004043A MX 2017004043 A MX2017004043 A MX 2017004043A MX 2017004043 A MX2017004043 A MX 2017004043A MX 2017004043 A MX2017004043 A MX 2017004043A MX 2017004043 A MX2017004043 A MX 2017004043A
Authority
MX
Mexico
Prior art keywords
acid derivatives
boronic acid
lmp7
inhibitors
employed
Prior art date
Application number
MX2017004043A
Other languages
English (en)
Inventor
Klein Markus
Schadt Oliver
Haselmayer Philipp
Busch Michael
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017004043A publication Critical patent/MX2017004043A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los compuestos de la fármula (I) son inhibidores de LMP7 y se pueden emplear, inter alia, para el tratamiento de un trastorno autoinmuitario o malignidades hematolágicas. (ver Fórmula).
MX2017004043A 2014-10-01 2015-10-01 Derivados de acido boronico. MX2017004043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14003391 2014-10-01
PCT/EP2015/001931 WO2016050356A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (1)

Publication Number Publication Date
MX2017004043A true MX2017004043A (es) 2017-07-04

Family

ID=51690788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004043A MX2017004043A (es) 2014-10-01 2015-10-01 Derivados de acido boronico.

Country Status (14)

Country Link
US (1) US10253049B2 (es)
EP (1) EP3201208B1 (es)
JP (1) JP6896618B2 (es)
KR (1) KR20170062518A (es)
CN (1) CN107074885B (es)
AU (1) AU2015327412B2 (es)
BR (1) BR112017006349A2 (es)
CA (1) CA2963198A1 (es)
ES (1) ES2876287T3 (es)
IL (1) IL251299A0 (es)
MX (1) MX2017004043A (es)
RU (1) RU2017115191A (es)
SG (1) SG11201702620SA (es)
WO (1) WO2016050356A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016050355A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
WO2016050358A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
CA2963205A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
KR102534947B1 (ko) * 2017-01-18 2023-05-23 프린시피아 바이오파마, 인코퍼레이티드 면역프로테아좀 억제제
JP7189203B2 (ja) * 2017-08-24 2022-12-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ボロン酸誘導体
US20200276204A1 (en) 2017-09-21 2020-09-03 Kezar Life Sciences Combination therapy for immunological diseases
BR112021001359A2 (pt) * 2018-07-26 2021-04-20 Merck Patent Gmbh derivados de ácido borônico
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
WO2023006863A1 (en) 2021-07-29 2023-02-02 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
US20240425529A1 (en) * 2021-10-14 2024-12-26 Shouyao Holdings (beijing) Co., Ltd. Boric acid derivative
CN117003776A (zh) * 2022-04-29 2023-11-07 科辉智药生物科技(深圳)有限公司 一种硼酸类蛋白酶体抑制剂及其用途
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
WO2006099261A2 (en) * 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
WO2009064413A1 (en) * 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
BR112012022060A2 (pt) * 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
KR20140114391A (ko) * 2011-12-22 2014-09-26 아레스 트레이딩 에스.에이. 알파-아미노 보론산 유도체, 선택적 면역프로테아좀 저해인자
CA2893460C (en) * 2012-12-03 2018-01-09 F. Hoffmann-La Roche Ag Substituted triazole boronic acid compounds
WO2016050358A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
CA2963205A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
WO2016050355A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives

Also Published As

Publication number Publication date
EP3201208A1 (en) 2017-08-09
CA2963198A1 (en) 2016-04-07
KR20170062518A (ko) 2017-06-07
JP6896618B2 (ja) 2021-06-30
AU2015327412A1 (en) 2017-05-18
AU2015327412B2 (en) 2020-01-16
RU2017115191A (ru) 2018-11-06
RU2017115191A3 (es) 2019-02-12
IL251299A0 (en) 2017-05-29
ES2876287T3 (es) 2021-11-12
JP2018502048A (ja) 2018-01-25
BR112017006349A2 (pt) 2017-12-12
US20180105538A1 (en) 2018-04-19
WO2016050356A1 (en) 2016-04-07
CN107074885B (zh) 2020-11-27
US10253049B2 (en) 2019-04-09
CN107074885A (zh) 2017-08-18
EP3201208B1 (en) 2021-03-24
SG11201702620SA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
PH12017500293A1 (en) Boronic acid derivatives
MX2017004037A (es) Derivados de acido boronico.
MX2017004043A (es) Derivados de acido boronico.
MX2017004046A (es) Derivados de acido boronico.
IL259787A (en) Mutant isocitrate dehydrogenase 1 (idh1) suppressor for the treatment of malignancies
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2016012829A (es) Inhibidores de biaril cinasa.
MX381417B (es) Inhibidores de glucosidasa.
PH12017500745A1 (en) Bromodomain inhibitors
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2016009355A (es) Inhibidores de aril lactama cinasa.
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MA39824A (fr) Composés azole amido-substitués
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
TN2016000208A1 (en) Novel compound for treatment of severe hypoglycemia.
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR
UA95450U (uk) 2-(6-етокси-2-метилхінолін-4-ілтіо)-сукцинатна кислота, що проявляє антиоксидантну активність